Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
Running, not enrolling · Phase 1 · Has a placebo group
Conditions studied: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
In brief
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Key facts
- Study ID
- NCT07205081
- Run by
- Attovia Therapeutics Inc
- People needed
- 72
- Starts
- 2025-10-22
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2026-05-28
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Attovia Clinical Site 203 — Encinitas, California, United States
- Attovia Clinical Site 202 — Saint Joseph, Missouri, United States
- Attovia Clinical Site 102 — Peterborough, Ontario, Canada
- Altasciences — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.